Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 Prophylaxis Versus Factor VIII Prophylaxis in Hemophilia A
NCT07416526Phase 3Recruiting
- Sponsor
- Roche
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of zemocimig in hemophilia A, sponsored by Roche. Started May 2026; status: recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07416526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416526.